JPMorgan Seeks Clarity On Dyne Therapeutics' DYNE-101 Expansion, Regulatory Path

BenzingaMar 22 01:38

J.P. Morgan Maintains Dyne Therapeutics(DYN.US) With Hold Rating, Cuts Target Price to $17

Futu NewsMar 22 01:31 · Ratings

Dyne Therapeutics Is Maintained at Neutral by JP Morgan

Dow JonesMar 22 00:28 · Ratings

Sector Update: Health Care Stocks Steady Premarket Friday

MT NewswiresMar 21 21:11

Express News | Dyne Therapeutics Inc : JP Morgan Cuts Target Price to $17 From $18

BreakingsMar 21 13:09

Dyne Therapeutics Names Editas Medicine's Lucera as CFO

WSJMar 21 05:14